Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Curis (CRIS) Stock Price & Analysis
1,286 Followers
CRIS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.47 - $2.63
Previous Close$0.54
Volume245.15K
Average Volume (3M)534.78K
Market Cap
$52.46M
Enterprise Value-$29.22M
Total Cash (Recent Filing)$85.62M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)-0.9
Beta1.22
Next Earnings
May 04, 2023EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding96,398,360
10 Day Avg. Volume312,085
30 Day Avg. Volume534,785
Standard Deviation0.66
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.41
Price to Sales (P/S)9.07
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.88
Enterprise Value/Gross Profit-2.95
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$7.00Price Target Upside1189.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Curis News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $0.47 and its highest was $2.63 in the past 12 months.
What is Curis Inc’s market cap?
Currently, no data Available
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is May 04, 2023 which is in 38 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on Mar 13, 2023. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.01.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -$0.1.
How many shares outstanding does Curis Inc have?
Curis Inc has 96,617,900 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of Curis Inc?
Among the largest hedge funds holding Curis Inc’s share is Maverick Capital ltd. It holds Curis Inc’s shares valued at 3M.
---
Curis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (1189.13% Upside)
$7.00 (1189.13% Upside)
Blogger Sentiment
Bullish
CRIS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.11%
12-Months-Change
Fundamentals
Return on Equity
-82.58%
Trailing 12-Months
Asset Growth
-32.84%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Curis Inc
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
---
Top 5 ETFs holding CRIS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold CRIS. The ETFs are listed according to market value of CRIS within the ETF
---
Disc Medicine
―
Longeveron
―
Decibel Therapeutics
―
Black Diamond Therapeutics
―
Aeglea Biotherapeutics
―
---